Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies

• প্রধান লেখক: Xiuwen Guan (লেখক), Fei Ma (লেখক), Qiao Li (লেখক), Shanshan Chen (লেখক), Bo Lan (লেখক), Ying Fan (লেখক), Jiayu Wang (লেখক), Yang Luo (লেখক), Ruigang Cai (লেখক), Pin Zhang (লেখক), Qing Li (লেখক), Binghe Xu (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: BMC, 2023-02-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Abstract Background Pyrotinib, a novel irreversible tyrosine kinase inhibitor (TKI), has demonstrated promising antitumor activity to improve the overall response rate and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer (MBC). However, the survival data of pyr...